Hypertension Clue to Better Outcomes with Avastin

Patients who developed hypertension with Avastin® (bevacizumab) had better response to treatment for colorectal cancer.  More had tumors shrink, and it took significantly longer for their cancer to get worse. In a small Italian study, researchers measured blood pressure in…  Read More

Two Different First-Line Irinotecan Treatments Have Similar Results

Spanish researchers have found that patients treated every week with Camptosar® (irinotecan, CPT-11) plus a high dose of  continuous infusion 5-FU (fluorouracil) without leucovorin had similar outcomes to those treated with the more common biweekly FOLFIRI treatment that includes leucovorin. …  Read More

Call for New Staging System for Advanced Colorectal Cancer

Experts in treating colorectal cancer that has spread to distant sites say that the need for a better staging system for advanced disease is urgent. More specific staging could identify patients whose cancer could be cured with surgery.  For others,…  Read More

KRAS Mutation Status Predicts Response to Erbitux in Canadian Study

Another study has shown that colon or rectal cancer patients whose tumors have mutated KRAS don’t benefit from Erbitux® (cetuximab).  However, in the study when only patients with normal or wild-type KRAS were considered, survival time almost doubled after treatment…  Read More

Xelox as Effective as FOLFOX after Colorectal Cancer Progresses

XELOX, as second-line therapy, was found to be as effective as the more commonly used FOLFOX treatment for patients whose cancer had already gotten worse on treatment with Camptosar® (irinotecan). XELOX combines an oral drug Xeloda® (capecitabine) with Eloxatin® (oxaliplatin). …  Read More